SION news

Latest 2 stories · newest Aug 10, 2026

SION

Sionna's SION-719 CF Program Misses Key Endpoint

Sionna missed the key activity endpoint for the SION-719 proof-of-concept trial, canceling development as an add-on to Trikafta. Despite the setback, the company maintains strong cash reserves and advanced its NBD1 dual combination trial.

Earnings Aug 10, 2026 sentiment -0.85 SEC filing ↗

SION

Sionna cancels PDUFA for drug candidate, cites business review

Sionna Therapeutics has voluntarily withdrawn its New Drug Application for STX001, which had a Prescription Drug User Fee Act date, to conduct a strategic business review. The company anticipates that the application will not be re-filed in its current form.

Regulatory Aug 6, 2026 sentiment -0.50 SEC filing ↗

BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.

The same SION feed as JSON for your bot or app:

GET https://api.brieftape.com/v1/tickers/SION/newsSTART FREE